Féray Cyrille, Campion Loic, Mathurin Philippe, Archambreaud Isabelle, Mirabel Xavier, Bronowicki Jean Pierre, Rio Emmanuel, Perret Christophe, Mineur Laurent, Oberti Frédéric, Touchefeu Yann, Gournay Jérôme, Regnault Hélène, Edeline Julien, Rode Agnès, Hillion Patrick, Blanc Jean Frédéric, Khac Eric Nguyen, Azoulay Daniel, Luciani Alain, Preglisasco Athena Galetto, Faurel-Paul Elodie, Auble Hélène, Mornex Françoise, Merle Philippe
Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.
Department of Biostatistics, Institut de Cancérologie de l'Ouest, Université Nantes, INSERM U307, Nantes, France.
JHEP Rep. 2023 Jan 29;5(4):100689. doi: 10.1016/j.jhepr.2023.100689. eCollection 2023 Apr.
BACKGROUND & AIMS: Transcatheter arterial chemoembolisation (TACE) is recommended for patients with hepatocellular carcinoma devoid of macrovascular invasion or extrahepatic spread but not eligible for curative therapies. We compared the efficacy and safety of the combination of a single TACE and external conformal radiotherapy (CRT) . classical TACE.
TACERTE was an open-labelled, randomised controlled trial with a 1:1 allocation rate to two or three TACE (arm A) or one TACE + CRT (arm B). Participants had a mean age of 70 years, and 86% were male. The aetiology was alcohol in 85%. The primary endpoint was liver progression-free survival (PFS) in the intention-to-treat population. The typical CRT schedule was 54 Gy in 18 sessions of 3 Gy.
Of the 120 participants randomised, 64 were in arm A and 56 in arm B; 100 participants underwent the planned schedule and defined the 'per-protocol' group. In intention-to-treat participants, the liver PFS at 12 and 18 months were 59% and 19% in arm A and 61% and 36% in arm B (hazard ratio [HR] 0.69; 95% CI 0.40-1.18; = 0.17), respectively. In the per-protocol population, treated liver PFS tended to be better in arm B (HR 0.61; 95% CI 0.34-1.06; = 0.081) than in arm A. Liver-related grade III-IV adverse events were more frequent in arm B than in arm A. Median overall survival reached 30 months (95% CI 23-35) in arm A and 22 months (95% CI 15.7-26.2) in arm B.
Although TACE + CRT tended to improve local control, this first Western randomised controlled trial showed that the combined strategy failed to increase PFS or overall survival and led more frequently to liver-related adverse effects.
Hepatocellular carcinoma is frequently treated by arterial embolisation of the tumour and more recently by external radiotherapy. We tried to determine whether combination of the two treatments (irradiation after embolisation) might produce interesting results. Our results in this prospective randomised study were not able to demonstrate a beneficial effect of combining embolisation and irradiation in these patients. On the contrary, we observed more adverse effects with the combined treatment.
NCT01300143.
对于无大血管侵犯或肝外转移但不适合根治性治疗的肝细胞癌患者,推荐行经动脉化疗栓塞术(TACE)。我们比较了单次TACE与体外适形放疗(CRT)联合治疗、传统TACE的疗效和安全性。
TACERTE是一项开放标签、随机对照试验,按1:1的分配比例分为两组或三组TACE(A组)或一次TACE + CRT(B组)。参与者的平均年龄为70岁,86%为男性。85%的病因是酒精性。主要终点是意向性治疗人群的无肝进展生存期(PFS)。典型的CRT方案是在18次每次3 Gy的照射中给予54 Gy。
在随机分组的120名参与者中,A组64名,B组56名;100名参与者接受了计划方案并定义为“符合方案”组。在意向性治疗参与者中,A组12个月和18个月时的肝PFS分别为59%和19%,B组分别为61%和36%(风险比[HR] 0.69;95%置信区间0.40 - 1.18;P = 0.17)。在符合方案人群中,B组的治疗后肝PFS(HR 0.61;95%置信区间0.34 - 1.06;P = 0.081)比A组更好。B组与肝脏相关的III - IV级不良事件比A组更频繁。A组的中位总生存期达到30个月(95%置信区间23 - 35),B组为22个月(95%置信区间15.7 - 26.2)。
尽管TACE + CRT倾向于改善局部控制,但这项首个西方随机对照试验表明,联合策略未能增加PFS或总生存期,且更频繁地导致与肝脏相关的不良反应。
肝细胞癌经常通过肿瘤动脉栓塞术治疗,最近也通过体外放疗治疗。我们试图确定两种治疗方法(栓塞后放疗)联合是否可能产生有趣的结果。我们在这项前瞻性随机研究中的结果未能证明在这些患者中联合栓塞和放疗有有益效果。相反,我们观察到联合治疗有更多不良反应。
NCT01300143。